P53 alterations have no prognostic or predictive significance in Dukes' C rectal carcinomas.
We investigated the prognostic significance of p53 alterations in a consecutive series of 122 Dukes' C rectal carcinomas with a median patient follow-up period of 56 months. One third of patients were treated with post-operative adjuvant chemotherapy. Overexpression of p53 protein was observed in 42% (50/118) of cases using immunohistochemical analysis and mutation of the p53 gene in 38% (47/122) using single strand conformation polymorphism technique. Neither p53 overexpression nor mutation were associated with significantly worse patient survival in the overall group or in the subgroup of 35 patients who received standard post-operative chemotherapy with 5-fluorouracil and levamisole. Our results do not support the use of p53 alteration as a clinically useful prognostic marker for the overall survival of rectal cancer patients or for predicting their response to chemotherapy.